Natixis Advisors
NBIX icon

Natixis Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Natixis Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
60,224
+16,627
+38% +$2.47M 0.01% 720
2026
Q1 		$5.74M Buy
43,597
+2,341
+6% +$311K 0.01% 803
2025
Q4 		$5.85M Sell
41,256
-1,530
-4% -$222K 0.01% 774
2025
Q3 		$6.01M Buy
42,786
+6,394
+18% +$866K 0.01% 788
2025
Q2 		$4.57M Buy
36,392
+3,080
+9% +$353K 0.01% 840
2025
Q1 		$3.68M Sell
33,312
-292
-0.9% -$37K 0.01% 887
2024
Q4 		$4.59M Buy
33,604
+4,277
+15% +$529K 0.01% 843
2024
Q3 		$3.38M Sell
29,327
-5,933
-17% -$813K 0.01% 932
2024
Q2 		$4.85M Buy
35,260
+3,531
+11% +$484K 0.01% 804
2024
Q1 		$4.38M Buy
31,729
+1,898
+6% +$259K 0.01% 834
2023
Q4 		$3.93M Sell
29,831
-512
-2% -$58.9K 0.01% 821
2023
Q3 		$3.41M Buy
30,343
+5,573
+22% +$587K 0.01% 824
2023
Q2 		$2.34M Sell
24,770
-29,481
-54% -$2.88M 0.01% 914
2023
Q1 		$5.49M Sell
54,251
-6,941
-11% -$722K 0.02% 665
2022
Q4 		$7.31M Sell
61,192
-9,270
-13% -$1.09M 0.03% 563
2022
Q3 		$7.48M Buy
70,462
+3,667
+5% +$372K 0.03% 509
2022
Q2 		$6.51M Buy
66,795
+6,446
+11% +$595K 0.03% 575
2022
Q1 		$5.66M Buy
60,349
+32,746
+119% +$2.78M 0.02% 642
2021
Q4 		$2.35M Sell
27,603
-13,419
-33% -$1.23M 0.01% 902
2021
Q3 		$3.93M Buy
41,022
+5,890
+17% +$556K 0.02% 717
2021
Q2 		$3.42M Buy
35,132
+1,094
+3% +$105K 0.02% 747
2021
Q1 		$3.31M Buy
34,038
+3,654
+12% +$383K 0.02% 732
2020
Q4 		$2.91M Sell
30,384
-3,632
-11% -$351K 0.02% 735
2020
Q3 		$3.27M Buy
34,016
+19,003
+127% +$2.2M 0.02% 655
2020
Q2 		$1.83M Buy
15,013
+446
+3% +$49.3K 0.01% 830
2020
Q1 		$1.26M Buy
14,567
+2,814
+24% +$275K 0.01% 845
2019
Q4 		$1.26M Buy
11,753
+1,135
+11% +$119K 0.01% 933
2019
Q3 		$957K Buy
+10,618
New +$992K 0.01% 941

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Natixis Advisors's NBIX Position: Q2 2026 in Review

Natixis Advisors increased its Neurocrine Biosciences (NBIX) stake by 38% in Q2 2026, buying an estimated $2.47M and bringing the position to 60,224 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #720.

Natixis Advisors first reported a position in NBIX in Q3 2019 and has held it in 28 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Natixis Advisors held 60,224 shares of Neurocrine Biosciences worth $10.1M as of Q2 2026.
  • Natixis Advisors bought 16,627 Neurocrine Biosciences shares in Q2 2026, an estimated $2.47M.
  • Neurocrine Biosciences made up 0.01% of Natixis Advisors's portfolio in Q2 2026, its #720 holding.
  • Natixis Advisors first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 28 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.